Essex Savings Bank Has $454,000 Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Essex Savings Bank raised its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 7.0% during the third quarter, Holdings Channel reports. The firm owned 5,830 shares of the company’s stock after buying an additional 382 shares during the period. Essex Savings Bank’s holdings in AstraZeneca were worth $454,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of AZN. Stratos Wealth Advisors LLC lifted its holdings in AstraZeneca by 2.0% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock worth $522,000 after buying an additional 133 shares during the period. Bruce G. Allen Investments LLC lifted its stake in AstraZeneca by 19.1% in the second quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company’s stock valued at $67,000 after purchasing an additional 138 shares during the last quarter. Carnegie Investment Counsel increased its holdings in shares of AstraZeneca by 0.8% in the second quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock worth $1,347,000 after purchasing an additional 138 shares during the period. Crumly & Associates Inc. increased its stake in AstraZeneca by 2.2% in the third quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock valued at $518,000 after acquiring an additional 143 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co grew its stake in shares of AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after buying an additional 146 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have commented on AZN. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday. TD Cowen lifted their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Stock Performance

Shares of NASDAQ:AZN opened at $64.49 on Friday. The company has a market capitalization of $199.96 billion, a price-to-earnings ratio of 31.15, a PEG ratio of 1.19 and a beta of 0.47. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The firm’s 50-day moving average is $77.07 and its 200 day moving average is $78.56. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.